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Background: Standardization of HDL-cholesterol is
needed for risk assessment. We assessed for the first time
the accuracy of HDL-cholesterol testing in The Netherlands
and evaluated 11 candidate reference materials (CRMs).
Methods: The total error (TE) of HDL-cholesterol mea-
surements was assessed in native human sera by 25
Dutch clinical chemistry laboratories. Concomitantly,
the suitability of lyophilized, saccharose-containing
CRMs (n 5 11) for HDL-cholesterol was evaluated.
Results: In the precipitation method group, which in-
cluded 25 laboratories and four methods, the mean
(minimum–maximum) TE was 11.5% (2.7–25.2%), signi-
fying that 18 of 25 laboratories satisfied the TE goal of
<13% issued by the National Cholesterol Education
Program (NCEP). In the homogeneous HDL-cholesterol
method group, which included five laboratories, each
performing two different methods, the mean (mini-
mum–maximum) TE was 9.5% (6.0–17.3%) for the Boehr-
inger assay and 15.7% (3.3–30.7%) for the Genzyme
assay. For the Boehringer homogeneous assay, one of
five laboratories did not meet the TE criterion, whereas
for the Genzyme homogeneous assay, three of five
laboratories exceeded the 13% criterion. The biases on
the HDL-cholesterol values found by various precipita-
tion methods were highly variable in all CRMs, irre-
spective of the quality, whereas the biases found by the
homogeneous method from Boehringer were far less
than 65% for the highest-quality CRMs (CRMs 4–6).
Conclusions: The NCEP goal was met by 24 of 35
laboratories assessed by use of native human sera.
Selectively pooled, lyophilized CRMs that are cryopro-
tected with 200 g/L saccharose have ample potential for
use in the standardization of homogeneous HDL-cho-
lesterol methods.
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Several prospective epidemiological studies and clinical
trials have demonstrated that low HDL-cholesterol (HDL-
chol)7 concentrations are an independent risk factor for
coronary heart disease (CHD); this inverse relationship is
maintained over a wide range of HDL-chol concentrations
(1, 2). Accordingly, HDL-chol determinations are in-
cluded in most national CHD prevention programs to
predict an individual’s risk and to guide treatment
(1, 3, 4). As an example, the latest revision of the Dutch
Cholesterol Consensus takes into account the cholesterol/
HDL-chol ratio for determining the absolute risk of indi-
viduals for developing CHD within the next decade,
besides classical risk factors as hypertension, diabetes
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mellitus, and family history (4 ). Analogously, the US
National Cholesterol Education Program (NCEP) Adult
Treatment Panel II has identified an HDL-chol concentra-
tion ,0.91 mmol/L as a major risk factor for CHD, and
considers HDL-chol concentrations .1.55 mmol/L as a
negative risk factor (3 ). Because of the enhanced demand
for measurement of HDL-chol in medical practice, precise
and accurate assays are warranted. To this end, the NCEP
Working Group on Lipoprotein Measurement issued per-
formance guidelines for HDL-chol analyses that all clini-
cal laboratories should achieve by 1998 (5 ). One goal is
that clinical laboratories should measure HDL-chol with a
total error (TE) #13%, which is achieved, for example, if
clinical laboratories have a mean bias of no more than
65% and perform with a CV #4% at $1.09 mmol/L.
To date, clinical chemistry laboratories frequently have
measured HDL-chol by chemical precipitation of the
apolipoprotein B (apoB)-containing lipoproteins with ei-
ther polyethylene glycol (PEG) 6000, dextran sulfate
(DS)/MgCl2 or phosphotungstic acid (PTA)/MgCl2, fol-
lowed by quantification of the cholesterol content in the
HDL-containing supernate (6 ). Standardization of these
HDL-chol assays is challenging because, in addition to
matrix effects, there is documented variability between
the commonly used precipitation reagents; these differ-
ences in precipitation efficiency and recovery become
obvious especially in lipemic sera (7–9). Therefore, homo-
geneous HDL-chol assays that no longer require sample
pretreatment have recently become attractive (10–14).
In The Netherlands, the accuracy of HDL-chol mea-
surements has not been investigated thus far. Conse-
quently, a pilot HDL-chol survey encompassing a repre-
sentative sample of 25 (14%) Dutch clinical laboratories
was conducted. The project was a joint project of both the
Lipid Reference Laboratory (LRL) Rotterdam and the
Dutch National External Quality Assurance Society,
named the SKZL. The survey aimed at documenting the
state-of-the-art accuracy, imprecision, and TE of the four
most commonly used second-generation methods and of
two recently introduced third-generation HDL-chol as-
says, using fresh human sera. Because periodical moni-
toring of the accuracy of HDL-chol measurements in the
Dutch proficiency testing program awaits the availability
of commutable reference materials, 11 candidate reference
materials (CRMs) with different concentrations of HDL-
chol and triglycerides were developed and investigated
for their suitability. The HDL-chol Designated Compari-
son Method (DCM) and the HDL-chol Reference Method
of the CDC were used as the reference methods (15, 16 ).
Materials and Methods
study design
Of 180 Dutch clinical chemistry laboratories participating
regularly in the National External Quality Assurance
Society scheme of the SKZL, 25 laboratories took part in a
pilot survey that aimed to assess the accuracy and impre-
cision of currently used routine HDL-chol methods. Apart
from the controlled inclusion of the type of method used
to measure HDL (see below), laboratory inclusion was
random, but known to be representative for the quality of
the Dutch laboratory healthcare system. Four academic
hospitals and 21 peripheral hospitals participated.
In the 25 laboratories, assessment of accuracy and
imprecision was performed using a standardized protocol
that was essentially based upon the cholesterol protocol
for certification of clinical laboratories developed by the
CDC [Mulder and Cobbaert, submitted for publication;
Refs. (15, 16 )]. In brief, accuracy was assessed using a
split-sample comparison with fresh human specimens
and performing duplicate measurements during 3 consec-
utive days. Between assays, native specimens were stored
at 4 °C. The overall imprecision of the field HDL-chol
methods was calculated from the repeated measurements
of the native sera. In parallel and in all three assays, the
suitability (or lack thereof) of the HDL-chol CRMs was
investigated. To this end, the HDL-chol CRMs were
freshly reconstituted at each occasion, i.e., for each assay.
HDL-chol value assignment was done centrally by the
LRL Rotterdam, using the CDC DCM for the native sera,
and using the CDC Reference Method or a modification of
that method for the CRMs.
native human sera
Because the traditional approaches for assessing accuracy
are complicated by matrix effects, the CDC strategy for
transferring accuracy from reference laboratories to clini-
cal laboratories was used (15, 16 ). To this end, 6 to 10
fresh, normotriglyceridemic (triglycerides ,2.26 mmol/L)
specimens from hospital workers, spanning the clinically
relevant HDL-chol range, were selected by each contrib-
uting laboratory (Mulder and Cobbaert, submitted for
publication). All sera were measured in duplicate in a
single assay during 3 consecutive days by each partici-
pant. Each day a new calibration was performed. Between
assays, sera were stored at 4 °C. These field HDL-chol
data were all gathered within 72 h after sample collection.
In addition, on the day of sample collection, aliquots of
each serum sample were stored at 220 °C or lower for
future value assignment by the LRL Rotterdam (15, 16 ).
CRMs for HDL-chol
CRMs intended to closely mimic fresh patient sera were
developed by the SKZL. Pools were prepared as described
previously (17 ). In total, 11 serum pools were made,
containing various concentrations of HDL-chol, triglycer-
ides, and cryo- and lyoprotectant (saccharose). Each pool
consisted of material originating from at least 150 differ-
ent patients. Before individual patient sera were frozen at or
below 220 °C, either 50 or 200 g/L saccharose was added to
each individual serum aliquot that was intended for use in
future pool preparation. By the time that a few liters of serum
pool were gathered per stratum, individual patient speci-
mens were thawed and mixed or supplemented as follows.
CRMs 1, 2, and 3, with low, medium, and high HDL-
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chol concentrations, were prepared by mixing the appro-
priate HDL-chol concentrations. The final saccharose con-
centration in CRMs 1–3 was maintained at 50 g/L. CRMs
4, 5, and 6, with low, medium, and high HDL-chol
concentrations, were prepared from the same mother
serum pools as those used for preparing CRMs 1, 2, and 3,
respectively. Before CRMs 4–6 were aliquoted and lyoph-
ilized, their final saccharose concentration was increased
to 200 g/L with additional saccharose. The addition of
saccharose caused volume expansion. To achieve nearly
equal HDL concentrations in the reconstituted CRMs, the
volumes before lyophilization were adjusted to 1 and 1.4
mL for specimens containing 50 and 200 g/L saccharose,
respectively. In the end, upon reconstitution in 1 mL of
distilled water, the final HDL-chol concentrations in
CRMs 4, 5, and 6 were somewhat higher than in CRMs 1,
2, and 3, respectively.
CRMs 7, 8, and 9, with low, medium, and high HDL-
chol concentrations, respectively, and a final saccharose
concentration of 200 g/L, were prepared from randomly
gathered serum aliquots that were initially frozen with
200 g/L saccharose. In contrast to the preparation of CRM
pairs 1 and 4 and 3 and 6, the low and high HDL-chol
concentrations in CRMs 7 and 9 were created by, respec-
tively, diluting or concentrating the randomly gathered
serum pool. Notably, total triglycerides were ,2.6
mmol/L in CRMs 1–9. Finally, CRMs 10 and 11, with
medium (4.85 mmol/L triglycerides, mainly VLDL) and
high concentrations of triglycerides (15.8 mmol/L triglyc-
erides, mainly chylomicrons), respectively, and a final
saccharose concentration of 200 g/L, were prepared from
appropriate serum aliquots that were initially frozen with
50 g/L saccharose. Sample preparation and subsequent
lyophilization of all CRMs was performed as described
previously (17 ).
sera used for the validation of the modified cdc
reference method procedure
A frozen serum pool from the CDC, i.e., AQ15, which is
usually used for internal and external quality-control
assessment of the HDL-chol Reference Method and the
HDL-chol DCM, was used for verifying the HDL-chol
accuracy in the 2-mL procedure compared with the 5-mL
procedure. In addition, precision was checked with two
freshly frozen single donor sera from hospital workers.
All pools were stored at 280 °C, and none contained
saccharose.
evaluation of lipoprotein integrity in the HDL-
chol CRMs
Reconstituted CRMs were first checked macroscopically
for turbidity. Lipoprotein integrity was then studied by
means of density gradient ultracentrifugation (UC) (17 ).
To this end, serum samples were stained with Coomassie
Brilliant Blue before UC, which yielded blue-colored lipo-
protein bands within the density gradient after UC. The
HDL-chol CRMs were then characterized by lipoprotein
electrophoresis with the Paragon system (Beckman Instru-
ments), with staining performed with Sudan Black (17).
Finally, because the CRMs were targeted with the CDC
Reference Method, the infranatants obtained after UC at
serum density were inspected visually and judged on the
basis of homogeneity, i.e., the absence or presence of flakes.
description of the various HDL-chol methods
used in this study protocol
CDC DCM used for accuracy assessment of normotriglyceri-
demic human sera. HDL-chol value assignment in both the
freshly frozen human specimens and the CRMs was
carried out by the LRL of the Academic Hospital Rotter-
dam, The Netherlands. The LRL Rotterdam is a perma-
nent, international member of the CDC Cholesterol Ref-
erence Method Laboratory Network (15, 16, 18 ). The
accuracy base for HDL-chol reportedly consists of the
CDC DCM (for normotriglyceridemic sera) and the CDC
Reference Method (for hypertriglyceridemic sera) (19 ).
The CDC DCM, a two-step procedure encompassing
Mr 50 000 DS/MgCl2 precipitation of apoB-containing
lipoproteins, and subsequent Abell-Kendall analysis (18 )
was used to determine HDL-chol concentrations in the
frozen native specimens sent by each participating labo-
ratory to the LRL. To this end, duplicate determinations
were performed in a single assay.
CDC Reference Method and modified CDC Reference Method
for value assignment of the CRMs for HDL-chol. The CDC
Reference Method, a three-step procedure consisting of an
UC step at serum density, heparin/MnCl2 precipitation of
apoB-containing lipoproteins, and subsequent Abell-Ken-
dall analysis, was used for targeting the CRMs. CRMs 1–3
were assigned values with the original CDC Reference
Method on the basis of quadruplicate determinations in
four independent assays.
In the presence of 200 g/L saccharose, no lipoprotein
separation could be achieved in CRMs 4–11, using the
original CDC HDL-chol Reference Method. Conse-
quently, the CDC Reference Method was modified. In
essence, the saccharose concentration was “diluted” to 80
g/L saccharose by pipetting 2.00 mL of CRM in a bell-top
Quick-Seal ultracentrifugation tube (Beckman Instru-
ments) and by overlayering with 3.00 mL of an electro-
lyte-albumin solution. The composition of the electrolyte-
albumin solution was critical because it affected the
HDL-chol recovery in the subsequent precipitation step,
i.e., HDL-chol recoveries were only complete if the over-
layering “diluent” contained physiological concentrations
of sodium, potassium, calcium, magnesium, chloride, and
protein. Bovine albumin (60 g/L) was used as a protein
source. Other than this modification, all other steps and
solutions used were similar to those of the CDC Reference
Method procedure. Note that after UC, chylomicrons
and/or VLDL were eliminated by cutting at a similar,
fixed height as in the 5-mL procedure. In addition, sub-
sequent recovery of the infranatant, which contained
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HDL and LDL, and the serum proteins was performed by
aspiration, washing of the inner side of the tube, and
dilution with 0.15 mol/L NaCl solution up to a final
volume of 5.00 mL. CRMs 4–11 were assigned values with
the modified CDC Reference Method, on the basis of
quadruplicate determinations in four independent assays.
The accuracy and the precision of the 2-mL procedure
was validated and compared with the analytical perfor-
mance of the 5-mL procedure, using fresh frozen human
sera and a frozen human serum control from the CDC.
Field HDL-chol methods. Four types of commercial precip-
itation methods were evaluated by the participating clin-
ical laboratories. Five of the participating laboratories
investigated, in parallel with their precipitation methods,
two recently introduced homogeneous HDL-chol assays.
The HDL-chol chemical precipitation methods were
assessed as follows: (a) the PEG 6000 method was as-
sessed at seven laboratories, using precipitation reagents
obtained from Merck (cat. no. 807491; three laboratories)
or from Instruchemie (cat. no. 2073; three laboratories), or
reagents prepared in house (one laboratory) (20, 21 ); (b)
the PTA/MgCl2 method was assessed at nine laborato-
ries, using precipitation reagents obtained from Boehr-
inger Mannheim (cat. no. 543004; eight laboratories) or
from Merck (cat. no. 114210; one laboratory); (c) the DS
(Mr 50 000)/MgCl2 method was assessed at six laborato-
ries, using precipitation reagents obtained from Beckman,
Johnson and Johnson, and Sigma; and (d) the PEG/DS/
MgCl2 was assessed at three laboratories, using precipi-
tation reagent obtained from Instruchemie (cat. no. 2258).
In the PEG/DS/MgCl2 precipitation method, the DS was
Mr 15 000 (22 ). In addition, the lyophilized version of the
homogeneous HDL-chol method from Boehringer (direct
HDL-chol reagent, cat. no. 1661426; calibrator f.a.s. HDL/
LDL-c, cat. no. 1778501) and the lyophilized N-geneousTM
HDL-chol method from Genzyme (direct HDL-chol re-
agent, cat. no. 2570; direct HDL-chol calibrator, cat. no.
2574) were evaluated.
In the homogeneous HDL-chol method from Boehr-
inger, sulfated a-cyclodextrin and DS form, at pH 7 and in
the presence of MgCl2, water soluble complexes with
LDL, VLDL, and chylomicrons (reagent 1), which are not
accessible to PEG-coupled cholesterol esterase and cho-
lesterol oxidase (reagent 2). In the Genzyme homo-
geneous HDL-chol method, a polyanion and synthetic
polymer (reagent 1) together form complexes with chylo-
microns, VLDL, and LDL particles and prevent them from
reacting with the second reagent, which is a mixture of
enzymes (cholesterol esterase, cholesterol oxidase, and
peroxidase), 4-aminoantipyrine, detergent, and buffer.
The HDL particles are disrupted by the detergent, thereby
releasing the cholesterol and cholesteryl esters. The HDL
concentration is then determined enzymatically, using a two-
point reaction. The homogeneous HDL-chol methods are
hereafter denoted as “a-cyclodextrin sulfate/PEG-coupled
enzyme” and “polymer/polyanion” assays, respectively.
In the chemical precipitation methods, the precipita-
tion steps for prior isolation of HDL were done manually,
whereas the cholesterol in the supernates was measured
on automated clinical chemistry analyzers. In the homo-
geneous HDL-chol methods, sample pretreatment was no
longer required, and fully automated applications were
used. Application was done according to the instructions
of the manufacturers, and all assays were performed with
calibrators that were included in the kits. Results were
scored after several assays in which reproducible results
were obtained.
statistics
In the method comparison study using native specimens,
overall analytical imprecision (CVa) was calculated from
measurement repeats, whereas mean laboratory biases
were calculated from the linear regression line fitted
between the HDL-chol data produced in the field (y-axis)
and the data produced with the HDL-chol DCM in the
LRL (x-axis). TE was calculated as: 1.96 3 CVa (%) 1
absolute mean bias (%). For final acceptance or rejection of
HDL-chol method performance, a TE criterion of #13%
was used (5 ).
To investigate the suitability of the CRMs for HDL-chol
standardization purposes or accuracy assessment, labora-
tory means and method group means (6 SD) were
calculated using basic statistics. Laboratory means of the
CRMs were compared with the target values assigned by
the LRL with either the CDC Reference Method or the
modified CDC Reference Method for HDL-chol. A signif-
icance level of a 5 0.05 was used throughout the study.
Results
method comparison of field HDL-chol methods
against the cdc HDL-chol dcm using
normotriglyceridemic, native human specimens
In the precipitation method group (n 5 25), the mean
(minimum–maximum range) percent TE, bias, and overall
imprecision were 11.5% (2.7–25.2%), 20.65% (214.2% to
11.5%), and 2.8% (0.8–8.0%), respectively (Fig. 1); i.e., 24
of 25 laboratories met the former interim TE goal of
#22%, whereas 18 of 25 laboratories satisfied the 1998 TE
goal of #13% (Fig. 1A). The bias criterion 65% or less was
met in 12 of 25 laboratories (Fig. 1B), and the precision
criterion of #4% was reached in 20 of 25 laboratories (Fig.
1C). The laboratories with HDL-chol biases exceeding
65% were distributed equally across different precipita-
tion methods; therefore, bias differences could not be
attributed to a specific manufacturer’s reagents or to a
specific analyzer (Fig. 1B).
In the homogeneous HDL-chol method group, the
mean (minimum–maximum range) percent TE, bias, and
overall imprecision were 9.5% (6.0–17.3%), 3.3% (26.4%
to 13.4%), and 1.9% (0.7–2.4%) for the a-cyclodextrin sul-
fate/PEG-coupled enzyme assay, and 15.7% (3.3–30.7%),
1.66%(213.1% to 34.2%), and 1.9% (1.2–2.8%) for the poly-
mer/polyanion assay. In the a-cyclodextrin sulfate/PEG-
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coupled enzyme assay group, one of five laboratories did
not meet the 1998 TE criterion, whereas in the polymer/
polyanion assay group, three of five laboratories exceeded
the 13% TE criterion because of excessive biases (Fig. 1).
The results of the linear regression analyses and the
analytical performance, averaged for the participating
laboratories per HDL-chol method group, are presented
in Table 1. In general, the slopes and intercepts scatter
around one and zero, respectively. However, for the
homogeneous polymer/polyanion assay, the slopes and
intercepts of the regression lines were significantly differ-
ent from one and zero, respectively (P ,0.05), both overall
and for individual participating laboratories. Overall im-
precision was far below 4% in each individual laboratory
performing either of the two homogeneous HDL-chol
methods. Conversely, the imprecision criterion was not
reached unanimously in individual laboratories perform-
ing chemical precipitation methods, with the exception of
the three laboratories performing the PEG/DS/MgCl2
precipitation method. The range of interlaboratory biases,
i.e., minimum–maximum range, was smallest and closest
to 0% in the PTA/MgCl2 method group (26.3% to 9.8%),
and largest in the homogeneous polymer/polyanion
method group (213.1% to 34.2%). TE was smallest for the
PEG and PTA/MgCl2 precipitation method groups, i.e.,
the maximum TE was ;15% and was largest for the
homogeneous polymer/polyanion method group.
characterization of the HDL-chol CRMs
After reconstitution of the CRMs a slight turbidity was
visible in CRMs 4–8, whereas a stronger turbidity
was observed in CRMs 1–3 and in CRMs 9–10. CRM 11
was found to be lipemic. The CRMs under study, both
with 50 and 200 g/L saccharose, exhibited well-defined a-
and b-lipoprotein bands, but faint or missing pre-b-
bands, especially in CRMs 1–3. Notably, some precipita-
Fig. 1. Percent TE (A), absolute mean bias (B), and overall
imprecision (C) of HDL-chol measurements in fresh human sera
surveyed in 25 Dutch clinical chemistry laboratories.
On the left of each panel are the data obtained from 25 laboratories
using second-generation HDL-chol precipitation methods; on the right of
each panel are HDL-chol data from five laboratories each performing two
homogeneous HDL-chol methods. The horizontal lines represent the
1998 NCEP goals.
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tion appeared at the application site as well as a smear of
indiscriminate staining between the application and the
b-region, being again much more pronounced in CRMs
1–3 than in CRMs 4–10. As an example, lipoprotein
patterns of CRMs 1–3 and CRMs 4–6 on agarose gel
electrophoresis are shown in Fig. 2,A and B, respectively.
For comparison, a normotriglyceridemic control was run
in lanes 7 and 8 of Fig. 2A.
In agreement with previous results (17 ), density-gra-
dient UC (data not shown) revealed sharp and well-
separated HDL2 and HDL3 bands in all CRMs. In addi-
tion, tiny flakes were observed at the interphase with the
atmosphere after UC. Flakes were also observed in the
CDC Reference Method: after UC at serum density mi-
nuscule flakes were observed in the infranatants in all
CRMs. More flakes were noted in CRMs 1–3 compared
with CRMs 4–11.
validation of the modified cdc HDL-chol
reference method procedure
The mean HDL-chol 6 SD (CV) for AQ15, as measured in
duplicate in 20 separate assays, was 1.288 6 0.029 mmol/L
(2.3%) when the 2-mL procedure was used. In comparison,
the mean HDL-chol 6 SD (CV) for AQ15, as measured in
duplicate in 20 assays, was 1.292 6 0.027 mmol/L (2.1%)
when the regular 5-mL procedure was used and 1.287 6
0.009 (0.7%) when the CDC DCM was used.
Analogously, in fresh-frozen single donor sera mea-
sured using duplicate spins in three separate assays, the
overall CVs obtained with the 2-mL procedure was 0.8%
at 2.24 mmol/L and 1.9% at 1.25 mmol/L.
Moreover, the accuracy of the modified CDC UC 2-mL
procedure for HDL-chol in the presence of 80 g/L saccha-
rose, i.e., the final saccharose concentration in the modi-
fied 2-mL procedure, was evaluated. Previously, the
HDL-chol concentration in a saccharose-supplemented
serum pool was compared with the HDL-chol target
value, as determined with the original 5-mL procedure in
an undiluted serum pool and with the modified 2-mL
procedure in the same, non-saccharose-supplemented,
diluted serum pool. Because weighing 80 g/L of saccha-
rose into serum pools diluted the pool 1.135-fold, the
non-saccharose-supplemented serum pool was, in case of
the 2-mL procedure and before UC, diluted to a similar
extent. The diluent was saline solution (9 g NaCl/L). In
each condition, HDL-chol value assignments were done
in quadruplicate in two different UC runs. When the 5-mL
UC procedure was used, the HDL-chol target value was
1.219 6 0.009 mmol/L (0.7%); in the 2-mL procedure, the
mean HDL-chol concentration was 1.214 6 0.035 mmol/L
(2.9%) in the non-saccharose-supplemented serum pool
and 1.203 6 0.021 (1.8%) mmol/L in the 80 g/L saccha-
rose-containing serum pool (not significant; P $0.05).
value assignment to the HDL-chol CRMs
The HDL-chol values assigned by the LRL Rotterdam to
the SKZL CRMs are presented in Table 2. Each target
value is the mean of quadruplicate analyses measured in
Table 1. Analytical performance of second-generation precipitation methods and third-generation homogeneous methods for
HDL-chol vs the HDL-chol DCM from the CDC.
Mean (minimum–maximum)
PEG
n 5 7a
PTA/MgCl2
n 5 9
DS/MgCl2
n 5 6
PEG/DS/MgCl2
n 5 3
a-Cyclodextrin
sulfate/PEG-coupled
enzymes
n 5 5
Polymer/polyanion
n 5 5
Linear regression analysis
Field HDL-c method group (y-axis) vs HDL-chol DCM (x-axis)b
Slope 1.017 1.071 1.008 0.953 1.055 0.802
(0.935–1.153) (0.947–1.209) (0.907–1.102) (0.864–1.007) (0.939–1.214) (0.719–0.858)
Intercept, mmol/L 20.026 20.056 20.032 20.044 20.019 0.240
(20.139 to 0.133) (20.145 to 0.042) (20.004 to 0.027) (20.182 to 0.091) (20.204 to 0.126) (0.037–0.729)
r 0.998 0.998 0.998 0.993 0.997 0.987
(0.984–1.000) (0.994–1.000) (0.997–0.999) (0.981–1.000) 0.991–1.000) (0.955–0.999)
Analytical performance characteristics of field HDL-chol method groups
Overall CVa, % 2.8 2.5 3.3 3.0 1.9 1.9
(0.8–5.1) (1.2–4.7) (1.0–8.0) (2.5–3.5) (0.7–2.6) (1.2–2.8)
Average bias, % 20.5 2.6 22.2 27.7 3.3 1.7
(28.9 to 11.5) (26.3 to 9.8) (29.4 to 9.5) (214.2 to 23.0) (26.4 to 13.4) (213.1 to 34.2)
TE, %c 11.3 10.1 13.0 13.6 9.5 15.7
(4.0–15.2) (2.7–15.1) (5.8–25.2) (9.9–20.3) (6.0–17.3) (3.3–39.7)
a n, number of laboratories.
b Field HDL-chol analyses were performed locally in 25 Dutch clinical chemistry laboratories using fresh, normotriglyceridemic human sera covering the HDL-chol
measuring range (n 5 6; duplicate analyses during three consecutive working days). HDL-chol DCM analyses were done centrally at the LRL Rotterdam, out of frozen
aliquots (duplicate analyses in one analytical run). Linear regression analysis was performed for each participating laboratory. Subsequently, the calculated parameters
were averaged per method group.
c TE (%) 5 1.96 3 CVa (%) 1 absolute average bias (%).
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four different assays, being produced with the CDC
Reference Method in the case of CRMs 1–3 and with the
modified CDC Reference Method in the case of CRMs 4–11.
CRMs were reconstituted freshly and pooled before each UC
run. Notably, SDs ranged between 0.043 and 0.166 mmol/L
and CVs between 2.7% and 10% (Table 2); i.e., SDs and CVs
in processed CRMs were three- to fivefold higher than those
obtained in frozen sera (see above).
performance of HDL-chol CRMs 1–11 for accuracy
assessment of HDL-chol precipitation methods
The dispersion of the mean HDL-chol concentrations
obtained in CRMs 1–11 by each participating laboratory—
the mean being based on duplicate analyses repeated
during 3 consecutive days—around the target values of
CRMs 1–11 is presented in Fig. 3. The outer horizontal
lines display the uncertainty on the values assigned by the
(modified) CDC Reference Method and represent the
mean 6 2 SD. From Fig. 3 it is obvious that there is a large
scatter of the mean HDL-chol values around the target
values. Nevertheless, most data fit within the mean plus
or minus the measuring error (expressed as SD) of the
reference range established with the (modified) CDC
Reference Method. Within each method group, interlabo-
ratory variability was similar for CRMs 1–10; however, in
the case of the chylomicron-rich CRM 11 the interlabora-
tory dispersion was more pronounced. Across method
groups, the PEG 6000 and the PTA/MgCl2 precipitation
methods performed better than the DS/MgCl2 method
both in terms of accuracy and in terms of interlaboratory
differences (Table 2). Conversely, the DS/MgCl2 had the
worst performance in combination with the lyophilized,
saccharose-containing CRMs, especially in the CRM con-
taining 200 g/L saccharose.
performance of HDL-chol CRMs 1–11 for accuracy
assessment of HDL-chol homogeneous methods
In the a-cyclodextrin sulfate/PEG-coupled enzyme assay,
the dispersion of the mean HDL-chol concentrations mea-
sured in CRMs 1–11 by each participating laboratory (four
laboratories; one laboratory failed to analyze the CRMs in
combination with the homogeneous HDL-chol methods)
around the target values of CRMs 1–11 was very moder-
ate, the mean from the participating laboratories being
well within the mean 6 2 SD confidence limits of the CDC
Reference Method (Fig. 3). From Table 2 it is obvious that
for CRMs 2–6 the mean HDL-chol values were within 6
1% of the assigned values. In the diluted CRM 7, the mean
HDL-chol values displayed a positive bias for all four
laboratories (overall mean bias, 5.4%), whereas in the
“concentrated” CRM 9 mean HDL-chol values were neg-
atively biased (overall mean bias, 27.2%). Even in hyper-
triglyceridemic CRMs, i.e., CRMs 10 and 11, which con-
tained 4.85 and 15.8 mmol/L triglycerides, respectively,
biases were less than 65%.
In the polymer/polyanion assay, a large spread in
mean HDL-chol values around the target values was
observed (Fig. 3 and Table 2), irrespective of the CRM
analyzed. These observations are in line with those ob-
served in native human sera.
Discussion
state-of-the-art analytical performance of
HDL-chol measurements in the netherlands
In HDL-chol assays, accuracy and precision of are critical
because clinical decisions are made using nationally de-
fined cutoff points that do not allow for methodological
error (3, 4). Whereas the precision of HDL-chol analyses is
monitored periodically in the SKZL, the Dutch profi-
ciency testing program provided by the Dutch National
External Quality Assurance Society, accuracy can only be
checked relative to the scores of colleagues (grand mean).
Absolute accuracy control is not possible at present be-
cause of a lack of suitable and stable (lyophilized) refer-
Fig. 2. Agarose gel electrophoresis of seven lyophilized HDL-chol CRMs
(CRMs 1–7), containing either 50 g/L saccharose (A) or 200 g/L
saccharose (B).
b-, pre-b-, and a-lipoproteins migrated at distances b, c, and d, respectively.
Some nonmigrating material was present at the application zone (a). CRMs 1–3
contained 50 g/L saccharose, whereas CRMs 4–7 contained 200 g/L saccha-
rose. All CRMs were applied twice, i.e., either diluted 1:1 with physiological
saline solution or undiluted. (A), lanes 7 and 8, fresh control serum.
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ence materials that have a long shelf half-life. To meet this
need, a pilot HDL-chol survey was conducted in 25 Dutch
clinical chemistry laboratories that aimed at documenting
the state-of-the-art analytical performance of HDL-chol
measurements in The Netherlands. Emphasis was put on
accuracy assessment using native, normotriglyceridemic
human sera. Because no performance recommendations for
HDL-cholesterol measurements have been developed by the
Dutch Clinical Chemistry Society thus far, the calculated
bias, imprecision, and TE were interpreted in the light of the
performance guidelines issued by the American NCEP
Working Group on Lipoprotein Measurement (5).
Excessive bias, exceeding 65%, was found to be
present in ;50% of the clinical chemistry laboratories
performing chemical precipitation methods (Fig. 1B). In
addition, because mean biases ranged between 214.2%
and 11.5%, interlaboratory differences between HDL-chol
measurements were as large as 25%, the latter observation
underscoring the findings of Crook (9 ) in 32 lipid clinics
in the United Kingdom. Excess bias was also observed in
three of five laboratories that implemented the homoge-
neous HDL-chol methods. In the direct a-cyclodextrin
sulfate/PEG-coupled enzyme method, the overall mean
bias of 3.3% was in line with previous findings of our
group (14 ). In the direct polymer/polyanion assay, ap-
parent improper reagent formulation and/or application
rather than improper value assignment of the calibrator
explained the observed findings (data not shown). Al-
though the survey was based on a small group, it seems
that the NCEP precision criterion of #4% was amply met
for the homogeneous HDL-chol methods compared with
the precipitation methods (Fig. 1C), probably because the
direct HDL-chol assays make the cumbersome manual
pretreatment step for isolation of HDL redundant.
The major advantages of this bias survey are related to
the fact that the targeting of the native sera was done in a
CDC Network Laboratory, using the recommended HDL-
chol accuracy bases (15, 16). In addition, firm conclusions
could be drawn from this survey because biases were
calculated from HDL-chol measurements performed in
fresh and native human sera, and the analysis of sixhu-
man sera on 3 consecutive days per laboratory led to an
acceptable uncertainty for the bias and TE estimates
(Mulder and Cobbaert, submitted for publication).
Assuming that the observed analytical performance of
the participating clinical laboratories for HDL-chol is
representative for The Netherlands, we concluded that
especially the accuracy, and to a lesser extent the preci-
sion, of conventional HDL-chol precipitation methods
were insufficient to satisfy the 1998 NCEP TE goal in
one-third of the clinical chemistry laboratories (Fig. 1A).
Whereas precision of the direct HDL-chol methods was
excellent (Fig. 1C), inaccurate results were obtained in
about one-half of the participating laboratories (Fig. 1B).
Consequently, the results from this pilot HDL-chol survey
underscore the urgent need for stable and commutable
calibration materials that emulate patient sera.
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evaluation of HDL-chol CRMs
Because improved nationwide accuracy awaits the avail-
ability of reference materials that are free of matrix effects,
are sufficiently stable to be shipped by overnight postage
without freezing, and have long-term stability (preferably
at 4 °C), an attempt was made to develop such CRMs for
HDL-chol. To this end, either 50 or 200 g/L saccharose
was weighed into serum pools to create different degrees
of cryo- and lyoprotection upon freezing and subsequent
lyophilization (17 ). A final saccharose concentration of
200 g/L was found to be a better protectant because
macroscopic turbidity after reconstitution of the lyophi-
lized CRMs was significantly less in CRMs 4–9 compared
with CRMs 1–3, the latter being cryoprotected with only
50 g/L of saccharose. However, reconstituted CRMs were
slightly turbid even in the presence of 200 g/L saccharose,
pointing to some degree of lipoprotein disintegration
and/or apolipoprotein denaturation. The observed tur-
bidity in the CRMs could be established on the basis of the
absorbance of the reconstituted materials at 620 nm (data
not shown), the presence of nonmigrating material at the
application site after agarose gel electrophoresis (Fig. 2),
and the presence of tiny flakes in the infranatants after UC
at serum density or at the interphase with the atmosphere
after density gradient centrifugation (data not shown).
The minuscule flakes probably were denatured apoB that
could no longer be dissolved, which was supported by the
faint or absent pre-b bands on agarose gel electrophoresis.
Subsequent value assignment of the CRMs with the
CDC HDL-chol Reference Method was hampered by the
high saccharose concentration, as reflected by the three- to
fivefold increases in CVs for targeting CRMs (Table 2)
Fig. 3. HDL-chol recovery in CRMs 1–11 as measured by four precipitation methods and two homogeneous HDL-chol methods .
1, PEG 6000; 2, PTA/MgCl2; 3, DS/MgCl2; 4, PEG/DS/MgCl2; 5, a-cyclodextrin sulfate/PEG-coupled enzymes; 6, polymer/polyanion. The thick horizontal lines
represent the assigned values as measured in 16-fold with either the CDC Reference Method or the modified CDC Reference Method for HDL-chol. The thin horizontal
lines represent the uncertainty on the assigned values, calculated as mean 6 2 SD. For each CRM and method group, the individual HDL-chol values of each
participating laboratory are given. Symbols indicate participating laboratories.
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compared with those of frozen single-donor sera and
frozen quality-control material (see Results). To target
CRMs 4–11, which contained 200 g/L saccharose, the
CDC HDL-chol Reference Method had to be modified. In
essence, the saccharose concentration in CRMs 4–11 was
diluted to 80 g/L before UC to enable lipoprotein sepa-
ration, which automatically adds a dilution factor of 2.5,
contributing greatly to the higher CVs. Because the accu-
racy of the modified CDC HDL-chol Reference Method
was within 0.5% of the target value obtained with the
original 5-mL procedure (mean 6 SD of 1.288 6 0.029
mmol/L for AQ15, using the 2-mL procedure, compared
with 1.292 6 0.027 mmol/L, using the official 5-mL
procedure) and because value assignment of each CRM
was based on 16 spins using either the Reference Method
or the Modified Reference Method, i.e., performing qua-
druplicate spins in four different UC runs, “target” values
for HDL-chol can be considered reliable and accurate.
In the present pilot HDL-chol survey, clinical chemis-
try laboratories analyzed freshly reconstituted CRMs in
duplicate in three separate assays. Per participant and per
CRM measured HDL-chol concentrations were averaged.
Fig. 3 shows that these HDL-chol concentrations were
highly variable both within and between precipitation
method groups. Because the between-run CVs of the
CRMs produced by individual laboratories did not differ
significantly from the between-run CVs produced with
internal, non-saccharose-based, quality-control material
(P $0.05; data not shown), it is unlikely that pipetting errors
caused by the high viscosity of the CRMs explain the
interlaboratory and intermethod differences. Probably, the
high amount of saccharose in the (manual) pretreatment
step interfered with HDL isolation. From the scattered
HDL-chol results around the assigned values (Fig. 3), we
concluded that saccharose-based reference materials cannot
be used for standardizing precipitation methods.
HDL-chol concentrations in the CRMs as measured by
all four laboratories that performed the a-cyclodextrin
sulfate/PEG-coupled enzyme assay were similar to those
obtained for fresh material, ranging between 93% and
105%. Likely, the 101-fold dilution of the saccharose
concentration in the final reaction mixture (4 mL of CRM
was incubated with 300 mL of R1 and 100 mL of R2) did
not interfere with assay specificity and HDL-chol recov-
ery. More specifically, HDL-chol recoveries were almost
ideal in CRMs 4–6, being 100% 6 1%. Because the
aforementioned CRMs 4–6 were pools of the highest
quality, these data support the validity of the targeting
procedure in the CRMs with the modified CDC Reference
Method. However, for CRM 7, the mean HDL-chol recov-
ery was 105.4%, whereas for CRM 9, the mean HDL-chol
recovery was 92.8%. The positive bias obtained in CRM 7
and the negative bias in CRM 9 can be linked to the
dilution or concentration of these pools, respectively, and
point to the sensitivity of the homogeneous method for
large variations in protein concentration. In CRMs 10 and
11, characterized by moderately increased concentrations of
triglycerides, HDL-chol recoveries were 96% and 99%, re-
spectively, illustrating the relative insensitivity of the Boehr-
inger direct HDL-chol method to hypertriglyceridemia.
In the polymer/polyanion method, the HDL-chol con-
centrations measured in the CRMs could not be inter-
preted because an unacceptable, method-related bias was
already disclosed in native human sera during the pilot
HDL-chol survey. The bias issue of the direct polymer/
polyanion method from Genzyme currently is solved in
the liquid formulation of the reagent because the reagent
formulation of the liquid HDL-chol assay differs distinctly
from that of the lyophilized version in that there is no
polymer in the first reagent, the magnesium concentration
has been reduced, an HDL-selective detergent has been
introduced in the second reagent, and the chromogens
4-aminoantipyrine and DSBmT have been segregated into
the first and second reagent, respectively. The different
modifications have been aimed successively at preventing
precipitation with alkaline wash solutions on analyzers
with reusable cuvettes; at improving assay specificity,
especially among hypertriglyceridemic specimens; at re-
ducing the background absorbance during the R1 phase;
and at improving the stability of the reagent blank. In
addition, the assay has incorporated a true endpoint
reading that is independent of analyzer cycling time, and
the wavelength selection has been changed (600 nm/700
nm instead of 546 nm/660 nm for the main and subsidiary
wavelengths, respectively) to reduce hemoglobin interfer-
ence. Consequently, the liquid version of the Genzyme
assay displays an overall mean bias of ,, 65% against the
CDC HDL-chol DCM in normotriglyceridemic sera.
Moreover, preliminary data from our group reveal that
the CRMs tested perform equally well with the latest
liquid version of the Genzyme direct HDL-chol method
and with the Boehringer direct HDL-chol method.
In conclusion, more effort must be made in The Nether-
lands to standardize HDL-chol methods to the CDC
Reference Method and/or to the CDC DCM and to reduce
method bias to less than 65%. To this end, the lyophi-
lized, saccharose-containing, human sera investigated
seem to have ample potential for use in standardizing
homogeneous HDL-chol methods. More specifically, the
selectively collected CRMs 4–6, prepared from lipopro-
tein-stabilized serum pools and having a normal protein
matrix with the exception of the presence of 200 g/L
saccharose, seem to be the first choice candidates for
future standardization of homogeneous HDL-chol assays
because the mean HDL-chol concentrations obtained in
CRMs 4–6 by the a-cyclodextrin sulfate/PEG-coupled
enzyme method were within 1% of the assigned values
obtained by the modified CDC Reference Method. Nev-
ertheless, more work must be done to investigate whether
the data can be extrapolated to all homogeneous HDL-
chol assays. Conversely, the viscous CRMs 1–11 cannot be
used for standardization of the HDL-chol precipitation
methods. However, it can be expected that virtually all
Clinical Chemistry 45, No. 3, 1999 369
clinical laboratories will switch to direct HDL-chol meth-
ods in the near future, abolishing the need for standard-
ization of precipitation methods.
We are grateful to the clinical chemists and technicians of
the participating laboratories who supported and enabled
this survey. We especially acknowledge Martin van Vliet
and Arjan van Dun from the Lipid Reference Laboratory,
Rotterdam, The Netherlands, for carrying out the (modi-
fied) CDC Reference Method and the CDC DCM for
HDL-chol, and Helga Toenhake-Dijkstra and Heidi Hak-
Lemmers of the Laboratory of General Internal Medicine,
Nijmegen, The Netherlands, for the careful and system-
atic pooling of sera and for the evaluation studies regard-
ing the quality and stability of the developed CRMs.
Appendix
participating dutch clinical laboratories
Academisch Ziekenhuis Leiden, Leiden; Academisch
Ziekenhuis Nijmegen, Nijmegen; Academisch Ziekenhuis
Rotterdam, Rotterdam; Academisch Ziekenhuis Vrije Uni-
versiteit Amsterdam, Amsterdam; Baronie Ziekenhuis,
Breda; BCO, Breda; Catharina Ziekenhuis, Eindhoven;
Eemland Ziekenhuis Lichtenberg, Amersfoort; Groot
Ziekengasthuis, ’s Hertogenbosch; Hofpoort Ziekenhuis,
Woerden; Holy Ziekenhuis, Vlaardingen; Leyenburg
Ziekenhuis, Den Haag; Maasland Ziekenhuis, Sittard;
Medisch Spectrum, Enschede; Sint-Anna Ziekenhuis, Gel-
drop; Sint-Lucas Ziekenhuis, Winschoten; Sint-Maartens
Gasthuis, Venlo; Spaarne Ziekenhuis, Heemstede; Stich-
ting KCL, Leeuwarden; Streekziekenhuis Koningin Beat-
rix, Winterswijk; Streekziekenhuis Walcheren, Vlissingen;
Westeinde Ziekenhuis, Den Haag; Ziekenhuis Am-
stelveen, Amstelveen; Ziekenhuis de Weezelanden,
Zwolle; and Zuiderziekenhuis, Rotterdam.
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